Hybridon, Inc.
Records under this name other than patents Hybridon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,749,975 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends Formerly held Term ended Term ended Aug 27, 2026 · From the USPTO record | Term ended | Term ended Aug 27, 2026 | From the USPTO record |
| US 7,569,554 | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents Formerly held Term ended Term ended May 6, 2026 · From the USPTO record | Term ended | Term ended May 6, 2026 | From the USPTO record |
| US 8,946,175 | Stabilized Immunomodulatory Oligonucleotides Formerly held Term ended Ended no later than Oct 10, 2025 · Low confidence | Term ended | Ended no later than Oct 10, 2025 | Low confidence |
| US 8,716,253 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes Formerly held Term ended Term ended Jun 28, 2025 · From the USPTO record | Term ended | Term ended Jun 28, 2025 | From the USPTO record |
| US 7,498,426 | Immunostimulatory oligonucleotide multimers Formerly held Term ended Term ended Apr 29, 2025 · From the USPTO record | Term ended | Term ended Apr 29, 2025 | From the USPTO record |
| US 7,427,405 | Immunostimulatory oligonucleotide multimers Formerly held Term ended Term ended Feb 9, 2025 · From the USPTO record | Term ended | Term ended Feb 9, 2025 | From the USPTO record |
| US 7,517,862 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends Formerly held Term ended Term ended Jun 9, 2024 · From the USPTO record | Term ended | Term ended Jun 9, 2024 | From the USPTO record |
| US 7,407,944 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends Formerly held Term ended Term ended Mar 4, 2024 · From the USPTO record | Term ended | Term ended Mar 4, 2024 | From the USPTO record |
| US 8,008,267 | Stabilized immunomodulatory oligonucleotides Formerly held Lapsed on the fee record Ended Aug 30, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 30, 2023 | From the USPTO record |
| US 7,276,489 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends Formerly held Term ended Term ended Jul 29, 2023 · From the USPTO record | Term ended | Term ended Jul 29, 2023 | From the USPTO record |